Risk Adapted Treatment of Myelofibrosis: A Focus on Quality-of-Life

Myelofibrosis is a rare myeloproliferative neoplasm associated with poor outcomes. Because early stages of disease are associated with minimal symptoms, most patients are diagnosed with advanced disease. In these patients, overall survival can be short and the risk of transformation to leukemia is high. To improve patient outcomes, it is important that high-risk patients with advanced disease are identified early and receive appropriate treatment. While historically there have been limited treatment options for advanced myelofibrosis, several novel JAK inhibitors have been approved in the past decade that significantly improve disease symptoms and overall survival, improving patient quality of life. However, use of these agents can be challenging, both in determining the optimal treatment selection, identifying when to switch therapies, and minimizing the impact of disease symptoms and treatment-related adverse events on patient quality-of-life.

Share

Program Content

Activities

  • A Focus on Quality-of-Life
    Risk Adapted Treatment of Myelofibrosis: A Focus on Quality-of-Life
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 22, 2022

    Expires: September 22, 2023

Faculty

cover img faculity

John Mascarenhas, MD

Director, Adult Leukemia Program
Leader, Myeloproliferative Disorders Clinical Research Program
Tisch Cancer Institute, Division of Hematology/Oncology
Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, NY

cover img faculity

Ruben Mesa, MD, FACP

Executive Director
Mays Cancer Center at UT Health San Antonio MD Anderson
Mays Family Foundation Distinguished University Presidential Chair
Professor of Medicine
San Antonio, TX

Provided by

ProCE Banner
ProCE Banner

Jointly provided by PCME and Rockpointe.

Supporters

This program is supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb